Biosergen AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOSGN.ST research report →
Companybiosergen.net
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
- CEO
- Tine Kold Olesen
- IPO
- 2021
- Employees
- 2
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $21.49M
- P/E
- -0.53
- P/S
- 0.00
- P/B
- 0.66
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -98.59%
- ROIC
- -127.07%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-40,817,000 · -112.64%
- EPS
- $-17.38 · -117.25%
- Op Income
- $-41,393,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $67.80
- 52W Low
- $9.00
- 50D MA
- $19.88
- 200D MA
- $38.91
- Beta
- -0.03
- Avg Volume
- 3.17K
Get TickerSpark's AI analysis on BIOSGN.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOSGN.ST Coverage
We haven't published any research on BIOSGN.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOSGN.ST Report →